User menu

Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.

Bibliographic reference Hillmen, Peter ; Muus, Petra ; Szer, Jeffrey ; Hill, Anita ; Höchsmann, Britta ; et. al. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.. In: American Journal of Hematology, Vol. 91, no. 3, p. E16-E17 (2016)
Permanent URL http://hdl.handle.net/2078.1/183419
  1. Koren E., Zuckerman L., Mire-Sluis A., Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction, 10.2174/1389201023378175
  2. Hwang William Ying Khee, Foote Jefferson, Immunogenicity of engineered antibodies, 10.1016/j.ymeth.2005.01.001
  3. Nechansky Andreas, HAHA – nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology, 10.1016/j.jpba.2009.07.013
  4. Brodsky R. A., Young N. S., Antonioli E., Risitano A. M., Schrezenmeier H., Schubert J., Gaya A., Coyle L., de Castro C., Fu C.-L., Maciejewski J. P., Bessler M., Kroon H.-A., Rother R. P., Hillmen P., Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria, 10.1182/blood-2007-06-094136
  5. Hillmen Peter, Hall Claire, Marsh Judith C.W., Elebute Modupe, Bombara Michael P., Petro Beth E., Cullen Matthew J., Richards Stephen J., Rollins Scott A., Mojcik Christopher F., Rother Russell P., Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria, 10.1056/nejmoa031688
  6. Hillmen Peter, Young Neal S., Schubert Jörg, Brodsky Robert A., Socié Gerard, Muus Petra, Röth Alexander, Szer Jeffrey, Elebute Modupe O., Nakamura Ryotaro, Browne Paul, Risitano Antonio M., Hill Anita, Schrezenmeier Hubert, Fu Chieh-Lin, Maciejewski Jaroslaw, Rollins Scott A., Mojcik Christopher F., Rother Russell P., Luzzatto Lucio, The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, 10.1056/nejmoa061648
  7. Hillmen Peter, Muus Petra, Röth Alexander, Elebute Modupe O., Risitano Antonio M., Schrezenmeier Hubert, Szer Jeffrey, Browne Paul, Maciejewski Jaroslaw P., Schubert Jörg, Urbano-Ispizua Alvaro, de Castro Carlos, Socié Gérard, Brodsky Robert A., Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria, 10.1111/bjh.12347
  8. Shankar G., Arkin S., Cocea L., Devanarayan V., Kirshner S., Kromminga A., Quarmby V., Richards S., Schneider C. K., Subramanyam M., Swanson S., Verthelyi D., Yim S., Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations, 10.1208/s12248-014-9599-2
  9. Soliris (eculizumab) [prescribing information] (2014)
  10. Baker Matthew, Reynolds Helen M., Lumicisi Brooke, Bryson Christine J., Immunogenicity of protein therapeutics: The key causes, consequences and challenges, 10.4161/self.1.4.13904